Company / R&D Expense
REGENXBIO Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$228.3M
FY2025
5-year range
$124.2M / $242.5M
FY2021-FY2025
Trend
+9.5%
vs FY2024
Sector context
#75 of 210
Health Care
What the data says
At $228M, REGENXBIO Inc.'s r&d expense ranks #75 of 210 in the Health Care sector. R&D Expense returned to growth in FY2025 after 2 years of decline, reaching $228M.
Based on SEC 10-K filings.
$228M in FY2025 with a 5-year CAGR of +22.2%.
Remained stable around $228M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -2.0%
- 5-Year CAGR
- +22.2%
- 10-Year CAGR
- -
Sector benchmark
#75 of 210 in Health CareTop 36% of 210This company $228.3M Sector average $644.0M
▼
-64.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +22.2%, indicating consistent growth.
- In FY2025, r&d expense increased 9.5% year-over-year.
- Ranks #75 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -2.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $228.3M | +9.5% |
| FY2024 | $208.5M | -10.2% |
| FY2023 | $232.3M | -4.2% |
| FY2022 | $242.5M | +95.2% |
| FY2021 | $124.2M | +48.1% |
| FY2020 | $83.9M | +46.6% |
| FY2019 | $57.2M | -31.8% |
| FY2018 | $83.9M | +46.6% |
| FY2017 | $57.2M | +1053.5% |
| FY2016 | $5.0M | -1.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026